Results 11 to 20 of about 11,095,042 (285)

Anti-vascular Endothelial Growth Factor Therapy (anti-VEGF) in the Treatment of Neovascular Membrane Secondary to Angioid Streaks – Case Report

Okulistyka
Angioid streaks, a rare defect of Bruch’s membrane, are most typically characterized by an asymptomatic course. However, when complications such as submacular hemorrhage or a neovascular membrane develop, visual acuity may deteriorate markedly, requiring
Karolina Agnieszka Korycińska, Agnieszka Cisek, Mariusz Spyra   +2 more
doaj   +2 more sources

The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy

Drugs in Context, 2018
Diabetes is a major cause of visual impairment among workingage adults in the United States. The proliferative form of diabetic retinopathy is associated with severe vision loss (acuity
Yue Zhao, Rishi P Singh
doaj   +2 more sources

Effects of anti-vascular endothelial growth factor monoclonal antibody (bevacizumab) on lens epithelial cells

Clinical Ophthalmology, 2016
Jong Hwa Jun,1 Wern-Joo Sohn,2 Youngkyun Lee,2 Jae-Young Kim21Department of Ophthalmology, School of Medicine, Dongsan Medical Center, Keimyung University, 2Department of Oral Biochemistry, School of Dentistry, IHBR, Kyungpook National University, Daegu,
Jun JH, Sohn WJ, Lee Y, Kim JY
doaj   +1 more source

Anti-cancer effects of F16: A novel vascular endothelial growth factor receptor–specific inhibitor

Tumor Biology, 2017
Vascular endothelial growth factor receptor-2 is a dynamic target for therapeutic intervention in various types of cancers. This study was aimed to explore the anti-angiogenic activity of a novel vascular endothelial growth factor receptor–specific ...
Appu Rathinavelu, Khalid Alhazzani, Sivanesan Dhandayuthapani, Thanigaivelan Kanagasabai   +3 more
doaj   +2 more sources

Epiretinal Membrane – What does It Change in Anti-vascular Endothelial Growth Factor Therapy Injection (anti-VEGF)?

Okulistyka
Epiretinal membrane is a type of fibrous proliferation on the retinal surface in the macular region. Its most common symptoms include metamorphopsia, micropsia, macropsia, and reduced visual acuity. When these symptoms are present, patients are typically
Paulina Glasner, Ewelina Serkies-Minuth, Katarzyna Michalska-Małecka   +2 more
doaj   +2 more sources

Vascular Targeted Agents for the Treatment of Angiosarcoma [PDF]

, 2013
Background: Angiogenesis is the process of new blood vessel formation, and is regulated by angiogenic growth factors including vascular endothelial growth factor (VEGF). Angiosarcomas are rare, aggressive vascular tumours.
P J Woll (16226153), R J Young (13425891), C A Staton (16226156), Malcolm Reed (4465876), Young, Robin, N J Brown (13424178)   +5 more
core   +6 more sources

Anti-vascular endothelial growth factor in ophthalmology

Indian Journal of Ophthalmology, 2009
Sinha Rajesh, Choudhary Sunil, Sinha Subijoy, Vashisht Nagender, Kumar Chandrashekhar   +4 more
doaj   +2 more sources

Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema

Clinical Ophthalmology, 2014
Szilárd Kiss,1 Ying Liu,2 Joseph Brown,3 Nancy M Holekamp,4,5 Arghavan Almony,6 Joanna Campbell,2 Jonathan W Kowalski2 1Weill Cornell Medical College, New York, NY; 2Allergan, Inc., Irvine, CA; 3IMS Health, Woodland Hills, CA; 4Pepose Vision ...
Kiss S, Liu Y, Brown J, Holekamp NM, Almony A, Campbell J, Kowalski JW   +6 more
doaj   +1 more source

Anti-vascular endothelial growth factor for neovascular glaucoma [PDF]

Cochrane Database of Systematic Reviews, 2009
Neovascular glaucoma (NVG) is a potentially blinding secondary glaucoma. It is caused by the formation of abnormal new blood vessels which prevent normal drainage of aqueous from the anterior segment of the eye. Anti-vascular endothelial growth factor (anti-VEGF) agents are specific inhibitors of the primary mediators of neovascularization.
Arathi, Simha, Andrew, Braganza, Lekha, Abraham, Prasanna, Samuel, Kristina, Lindsley   +4 more
openaire   +4 more sources

Biomarkers for anti‑vascular endothelial growth factor drugs

Oncology Letters, 2022
Angiogenesis is regulated by interactions between vascular endothelial growth factors (VEGFs) and VEGF receptors. VEGF-A, VEGF-D, placental growth factor (PlGF) and plasminogen activator inhibitor-1 (PAI-1) have tumor angiogenic activity. VEGF-A and PAI-1 levels in the blood may impact the activity of bevacizumab, and VEGF-D levels may similarly ...
Kuriyama, Sho, Yamada, Takeshi, Matsuda, Akihisa, Takahashi, Goro, Iwai, Takuma, Takeda, Kohki, Ueda, Koji, Miyasaka, Toshimitsu, Yokoyama, Yasuyuki, Shinji, Seiichi, Sonoda, Hiromichi, Ohta, Ryo, Yonaga, Kazuhide, Kanaka, Shintaro, Yoshida, Hiroshi   +14 more
openaire   +2 more sources